查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092193

乳房切片市場－2026-2032年全球市場預測

Breast Biopsy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳房切片市場規模將達到 34.2 億美元，複合年成長率為 6.67%。

主要市場統計數據
基準年 2025 21.7億美元
預計年份：2026年 23.1億美元
預測年份 2032 34.2億美元
複合年成長率 (%) 6.67%

乳房切片執行摘要：現代乳癌治療中的精準診斷

乳房切片是一項重要的診斷程序，用於評估透過乳房X光攝影、超音波、磁振造影（MRI）或臨床檢查發現的乳房可疑病變。它能夠對組織樣本進行組織病理學評估，有助於制定治療方案，並在影像引導的微創技術適用時避免不必要的手術干預，從而支持乳癌的早期準確診斷。空芯針穿刺切片、真空輔助乳房切片、細針穿刺切片檢查、立體定位切片檢查、超音波導引切片檢查和MRI引導切片檢查等技術正日益被納入乳癌的多學科治療流程中。

乳房切片領域的變革性變化

在乳房切片領域，正從開放式手術切片檢查轉向以影像引導的微創、以患者為中心的診斷方法。當影像學檢查觀察提示病灶時，臨床指引越來越建議經皮切片檢查。這是因為，與切除活體組織切片相比，經皮穿刺切片檢查既能獲取足夠的組織樣本進行診斷，又能減少恢復時間、疤痕形成和手術負擔。這進一步強化了放射科與病理科之間的協作、病灶識別以及標準化報告系統在提高診斷準確性方面的作用。

人工智慧對乳房切片工作流程的累積影響

人工智慧 (AI) 正開始影響乳房切片的整體診斷流程，尤其是在基於影像的分流、病灶特徵分析、切片檢查計劃制定、病理學審查和工作流程最佳化方面。在乳房攝影影像學領域，AI 驅動的決策支援可以幫助臨床醫生識別乳房X光攝影、超音波和 MRI 中的可疑觀察，並確定需要進一步診斷評估的病例的優先順序。在介入放射學領域，AI 可以輔助穿刺路徑規劃、病灶定位、影像抗蝕劑和品管，尤其適用於複雜或微小病灶。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區乳癌患者群龐大且組成複雜，乳癌篩檢力度不斷加大，都市區醫院和專科醫療中心對影像設備的投入也日益增加。醫療體系成熟的國家擴大採用磁振造影切片檢查和真空輔助切片檢查，而新興經濟體則致力於提高超音波切片檢查和空芯針穿刺活體組織切片的普及率。公眾意識的宣傳活動以及乳癌負擔的日益加重，進一步凸顯了早期診斷的必要性。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體分析

在東南亞國協，隨著國家癌症控制計畫、私人診斷網路​​和都市區醫院系統擴大了乳房X光檢查、超音波和病理檢測的覆蓋範圍，乳房切片的普及率正在不斷提高。該地區的優先事項包括提高早期發現率、加強轉診途徑以及縮小都市區人口之間的差距。

各國在乳房切片引入和診斷可及性方面的關鍵見解

在美國，乳房切片的環境高度發達，這得益於廣泛的影像診斷、專業的乳癌中心、介入放射學技術以及基於生物標記的腫瘤診療路徑。在加拿大，系統性篩檢、全民健保和標準化的轉診途徑至關重要，但地理距離可能會影響偏遠地區及時獲得診斷。在墨西哥，公共衛生計畫和私人診斷機構的互補作用不斷加強乳癌篩檢。巴西是拉丁美洲主要的乳癌醫療市場之一，先進的醫療服務集中在主要城市，但確保各地區公平地獲得醫療服務仍然是一項挑戰。

為乳房切片行業領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗、以工作流程為導向的乳房切片解決方案，以提高診斷準確性、組織樣本量、患者舒適度和手術效率。產品開發應著重於影像引導的準確性、符合人體工學的儀器設計、檢體品質控制、與分子檢測的兼容性以及與數位放射線和病理學系統的整合。增強有助於放射學和病理學觀察一致性的工具、檢體追蹤系統和結構化報告系統可以減少診斷延誤，並增強治療決策的信心。

基於證據的乳房切片調查方法

本執行摘要採用結構化的二手研究途徑編寫，以檢驗的臨床、監管和公共衛生資訊來源為中心。調查方法包括審查經認可的衛生機構所進行的乳癌流行病學調查、乳房病變評估的臨床實踐指南、關於影像導引切片檢查技術的同行評審文獻，以及關於篩檢計畫、診斷基礎設施和醫療保健系統能力的公開資訊。

結論：乳房切片是早期、更準確診斷癌症的基礎

乳房切片仍然是乳癌診斷的關鍵環節，它將影像檢查中發現的可疑觀察與最終的病理觀察以及基於生物標記的治療方案聯繫起來。微創技術、影像引導技術的改進、數位病理學、人工智慧驅動的工作流程以及更緊密的多學科協作正在推動該領域的發展。這些進步提高了診斷的準確性，並有助於以患者為中心的護理和更有效率的癌症治療過程。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章乳房切片市場：依產品類型分類

  • 切片穿刺針
  • 導航系統
  • 癌症切片檢查
  • 耗材和配件

第8章：乳房切片市場：依手術類型分類

  • 粗針穿刺切片
  • 真空輔助切片檢查
  • 細針穿刺切片檢查
  • 手術/開放式切片檢查
    • 切除切片檢查
    • 切片檢查

第9章乳房切片市場：方法論指導

  • 超音波引導下切片檢查
  • 立體定位X光引導切片檢查
  • 磁振造影引導切片檢查

第10章：乳房切片市場：依切片檢查部位分類

  • 乳房組織
  • 腋窩和區域淋巴結
  • 乳頭導管結構

第11章：乳房切片市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章：乳房切片市場：依適應症分類

  • 早期癌症篩檢
  • 治療方案
  • 復發和治療監測

第13章：乳房切片市場：按地區分類

  • 北美洲
  • 亞太地區
  • 歐洲
  • 非洲
  • 中東
  • 拉丁美洲

第14章乳房切片市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第15章乳房切片市場：按國家分類

  • 美國
  • 德國
  • 中國
  • 日本
  • 加拿大
  • 法國
  • 印度
  • 英國
  • 墨西哥
  • 義大利
  • 韓國
  • 澳洲
  • 俄羅斯
  • 巴西
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Danaher Corporation
  • FUJIFILM Corporation
  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • CooperSurgical, Inc.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Bio-Rad Laboratories, Inc
  • Argon Medical Devices, Inc.
  • Sysmex Corporation
  • Trivitron Healthcare
  • Resitu Medical AB
  • A.Menarini Industrie Farmaceutiche Riunite Srl
  • Canon Medical Systems Corporation
  • Cook Group Incorporated
  • Exact Sciences Corporation
  • Guardant Health, Inc.
  • Halma PLC
  • INRAD, Inc.
  • Johnson & Johnson Services Inc.
  • Koninklijke Philips NV
  • Medax Srl Unipersonale
  • Planmed Oy
  • QIAGEN NV
  • STERYLAB Srl
  • Thermo Fisher Scientific Inc.
  • TransMed7, LLC
Product Code: MRR-4F4C36263235

The Breast Biopsy Market is projected to grow by USD 3.42 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.17 billion
Estimated Year [2026] USD 2.31 billion
Forecast Year [2032] USD 3.42 billion
CAGR (%) 6.67%

Breast Biopsy Executive Summary: Precision Diagnosis in Modern Breast Cancer Care

Breast biopsy is a critical diagnostic procedure used to evaluate suspicious breast lesions identified through mammography, ultrasound, magnetic resonance imaging, or clinical examination. It supports early and accurate breast cancer diagnosis by enabling histopathological assessment of tissue samples, guiding treatment planning, and reducing unnecessary surgical intervention when image-guided, minimally invasive techniques are appropriate. Core needle biopsy, vacuum-assisted breast biopsy, fine needle aspiration, stereotactic biopsy, ultrasound-guided biopsy, and MRI-guided biopsy are increasingly integrated into multidisciplinary breast care pathways.

The demand for breast biopsy procedures is shaped by rising breast cancer incidence, broader participation in screening programs, increased use of advanced breast imaging, and clinical emphasis on precise tumor characterization, including hormone receptor and HER2 status. Public health authorities consistently identify breast cancer as the most commonly diagnosed cancer among women worldwide, reinforcing the importance of timely diagnostic confirmation. In this context, breast biopsy technologies, pathology workflows, specimen handling systems, localization tools, and digital diagnostic infrastructure are becoming central to evidence-based oncology care.

Transformative Shifts in the Breast Biopsy Landscape

The breast biopsy landscape is undergoing a shift from open surgical biopsy toward image-guided, minimally invasive, and patient-centered diagnostic approaches. Clinical guidelines increasingly favor percutaneous biopsy when imaging findings are suspicious, as it can provide adequate tissue for diagnosis while reducing recovery time, scarring, and procedural burden compared with excisional biopsy. This has strengthened the role of radiology-pathology coordination, lesion localization, and standardized reporting systems in improving diagnostic confidence.

Another transformative shift is the rising importance of tissue adequacy for personalized oncology. Breast biopsy samples are no longer used only to confirm malignancy; they also support biomarker testing, molecular profiling, and therapy selection. Advances in digital pathology, automated tissue processing, high-resolution imaging, and specimen tracking are improving workflow reliability across hospitals, diagnostic centers, and cancer institutes. At the same time, patient experience is receiving greater attention through improved pain control, shorter procedure times, better communication, and streamlined same-day diagnostic pathways.

Cumulative Impact of Artificial Intelligence on Breast Biopsy Workflows

Artificial intelligence is beginning to influence breast biopsy across the diagnostic continuum, especially in imaging triage, lesion characterization, biopsy planning, pathology review, and workflow optimization. In breast imaging, AI-enabled decision support can assist clinicians in identifying suspicious findings on mammograms, ultrasound, and MRI, which may help prioritize cases for further diagnostic evaluation. In interventional radiology, AI has potential to support needle path planning, lesion targeting, image registration, and quality control, particularly for complex or small lesions.

In pathology, AI-assisted image analysis can help highlight areas of interest on digitized slides, support consistency in tumor grading, and improve efficiency in high-volume laboratories when used under expert oversight. The cumulative impact of AI is therefore not a replacement of clinical judgment but an enhancement of diagnostic accuracy, reproducibility, turnaround time, and resource allocation. Responsible deployment requires validated algorithms, transparent performance metrics, bias monitoring across diverse populations, cybersecurity safeguards, and compliance with medical device and data protection regulations.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is shaped by a large and diverse patient population, expanding breast cancer screening initiatives, and growing investment in diagnostic imaging capacity across urban hospitals and specialty centers. Countries with mature healthcare systems are advancing MRI-guided and vacuum-assisted biopsy adoption, while emerging economies are focused on improving access to ultrasound-guided and core needle biopsy services. Population awareness campaigns and the rising burden of breast cancer are reinforcing the need for earlier diagnostic confirmation.

North America demonstrates advanced integration of breast biopsy into organized imaging, oncology, and pathology pathways. Widespread availability of mammography, ultrasound, MRI, interventional radiology expertise, and molecular testing supports high utilization of image-guided biopsy. Clinical practice is also influenced by established accreditation frameworks, breast imaging reporting standards, and a strong emphasis on shared decision-making.

Latin America is progressing through investments in cancer detection, public-private diagnostic partnerships, and expansion of specialized breast units. Access remains uneven between major metropolitan hospitals and underserved areas, making portable ultrasound, training programs, and referral network efficiency important for improving timely biopsy access. Europe benefits from structured screening programs, multidisciplinary cancer boards, and rigorous quality assurance systems. Many countries emphasize standardized breast assessment pathways, radiology-pathology concordance, and adherence to evidence-based diagnostic protocols.

The Middle East is experiencing rising demand for breast biopsy due to expanding oncology infrastructure, national screening campaigns, and growing adoption of advanced imaging in tertiary hospitals. GCC health systems are particularly active in developing specialized cancer centers and women's health services. Africa faces the greatest access challenges, with late-stage presentation, limited screening coverage, and shortages of imaging and pathology capacity in several settings. However, targeted public health programs, workforce training, and investment in diagnostic infrastructure are improving the foundation for earlier breast cancer diagnosis.

Key Group Insights Covering ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries show increasing momentum in breast biopsy adoption as national cancer control programs, private diagnostic networks, and urban hospital systems expand access to mammography, ultrasound, and pathology services. The region's priorities include improving early detection, strengthening referral pathways, and reducing disparities between urban and rural populations.

The GCC is characterized by high investment in tertiary healthcare, women's health initiatives, and specialized oncology centers. Breast biopsy services are increasingly supported by advanced imaging platforms, international clinical protocols, and government-led screening awareness programs. The European Union benefits from coordinated screening policies, strong regulatory oversight, and cross-border alignment on quality standards for breast cancer diagnosis, with emphasis on evidence-based biopsy selection and pathology quality assurance.

BRICS countries present a mixed but influential diagnostic environment. China and India are expanding screening and biopsy capacity to address large patient populations, Brazil and South Africa are focused on improving access and regional equity, and Russia maintains broad public oncology infrastructure with ongoing modernization needs. G7 countries generally demonstrate mature breast biopsy ecosystems supported by established imaging networks, pathology services, reimbursement structures, and clinical guideline adoption. NATO member countries, many of which overlap with North America and Europe, often benefit from advanced hospital infrastructure, medical technology availability, and standardized clinical training, although access levels vary by national healthcare system.

Key Country Insights for Breast Biopsy Adoption and Diagnostic Access

The United States has a highly developed breast biopsy environment supported by broad imaging access, breast centers, interventional radiology expertise, and biomarker-driven oncology pathways. Canada emphasizes organized screening, universal healthcare access, and standardized referral pathways, though geographic distance can affect timely diagnostic access in remote regions. Mexico continues to strengthen breast cancer detection capacity, with public health programs and private diagnostic providers playing complementary roles. Brazil is one of Latin America's key breast cancer care markets, with advanced services concentrated in major cities and continued need for equitable access across regions.

The United Kingdom has established breast screening and assessment pathways that integrate imaging, biopsy, pathology, and multidisciplinary review. Germany benefits from strong diagnostic infrastructure, certified breast centers, and high adoption of image-guided biopsy techniques. France emphasizes organized screening, radiology quality assurance, and coordinated oncology care, while Italy and Spain maintain robust breast units and guideline-based diagnostic assessment across public and private settings. Russia has broad oncology service coverage, with modernization of imaging and pathology capacity remaining important for diagnostic consistency.

China is rapidly expanding breast imaging, hospital oncology capacity, and pathology modernization to meet rising diagnostic needs. India faces a dual landscape of advanced tertiary cancer centers and significant access gaps, making affordable ultrasound-guided biopsy, awareness, and workforce development central priorities. Japan has mature imaging and pathology systems, with attention to precision diagnostics and minimally invasive biopsy techniques. Australia benefits from national screening infrastructure, high-quality radiology services, and multidisciplinary cancer care. South Korea is marked by strong healthcare technology adoption, high imaging utilization, and advanced hospital-based breast cancer diagnostic pathways.

Actionable Recommendations for Breast Biopsy Industry Leaders

Industry leaders should prioritize clinically validated, workflow-friendly breast biopsy solutions that improve diagnostic accuracy, tissue adequacy, patient comfort, and procedural efficiency. Product development should focus on image-guided precision, ergonomic device design, specimen quality preservation, compatibility with molecular testing, and integration with digital radiology and pathology systems. Strengthening radiology-pathology concordance tools, specimen tracking, and structured reporting can help reduce diagnostic delays and improve confidence in care decisions.

Organizations should also invest in training programs for radiologists, surgeons, technologists, and pathology teams, especially in regions where biopsy access is limited by workforce constraints. Partnerships with hospitals, cancer centers, public health programs, and professional societies can support evidence-based adoption. AI-enabled solutions should be deployed with rigorous clinical validation, local population testing, explainability, and data governance. For long-term competitiveness, leaders should align innovation with screening expansion, minimally invasive care, decentralized diagnostics, and equitable access to breast cancer diagnosis.

Research Methodology for Evidence-Based Breast Biopsy Insights

This executive summary is developed using a structured secondary research approach centered on verified clinical, regulatory, and public health sources. The methodology includes review of breast cancer epidemiology from recognized health authorities, clinical practice guidelines for breast lesion assessment, peer-reviewed literature on image-guided biopsy techniques, and publicly available information on screening programs, diagnostic infrastructure, and healthcare system capabilities.

The analysis evaluates breast biopsy through procedure type, imaging guidance, end-user setting, regional healthcare maturity, access conditions, and technology adoption trends. Findings are synthesized qualitatively to identify diagnostic workflow shifts, AI-related implications, regional differences, and strategic priorities. The research intentionally excludes market estimation, market sizing, market share, and forecasting, focusing instead on evidence-backed industry dynamics, clinical relevance, and decision-useful insights for stakeholders in breast cancer diagnostics.

Conclusion: Breast Biopsy as a Foundation for Earlier and More Precise Cancer Diagnosis

Breast biopsy remains an indispensable component of breast cancer diagnosis, connecting suspicious imaging findings with definitive pathology and biomarker-driven treatment planning. The field is advancing through minimally invasive techniques, improved imaging guidance, digital pathology, AI-supported workflows, and stronger multidisciplinary collaboration. These developments are improving diagnostic precision while supporting patient-centered care and more efficient oncology pathways.

Regional progress varies significantly, with mature healthcare systems emphasizing quality assurance and advanced guidance technologies, while emerging settings focus on access expansion, workforce development, and pathology capacity. Across all markets, the most important opportunities center on earlier diagnosis, reliable tissue sampling, streamlined workflows, and equitable access to high-quality breast biopsy services. Stakeholders that align innovation with clinical validation, interoperability, and patient outcomes will be best positioned to support the next phase of breast cancer diagnostic care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Breast Biopsy Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biopsy Needles
  • 7.3. Guidance Systems
  • 7.4. Biopsy Guns
  • 7.5. Consumables & Accessories

8. Breast Biopsy Market, by Procedure Type

  • 8.1. Introduction
  • 8.2. Core Needle Biopsy
  • 8.3. Vacuum-Assisted Biopsy
  • 8.4. Fine Needle Aspiration Biopsy
  • 8.5. Surgical/Open Biopsy
    • 8.5.1. Excisional Biopsy
    • 8.5.2. Incisional Biopsy

9. Breast Biopsy Market, by Guidance Modality

  • 9.1. Introduction
  • 9.2. Ultrasound-Guided Biopsy
  • 9.3. Stereotactic X-Ray-Guided Biopsy
  • 9.4. MRI-Guided Biopsy

10. Breast Biopsy Market, by Biopsy Site

  • 10.1. Introduction
  • 10.2. Breast Parenchyma
  • 10.3. Axillary & Regional Lymph Nodes
  • 10.4. Nipple & Ductal Structures

11. Breast Biopsy Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgery Centers
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Breast Biopsy Market, by Clinical Indication

  • 12.1. Introduction
  • 12.2. Early Cancer Screening
  • 12.3. Therapy Selection
  • 12.4. Recurrence & Treatment Monitoring

13. Breast Biopsy Market, by Region

  • 13.1. North America
  • 13.2. Asia-Pacific
  • 13.3. Europe
  • 13.4. Africa
  • 13.5. Middle East
  • 13.6. Latin America

14. Breast Biopsy Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. ASEAN
  • 14.6. GCC

15. Breast Biopsy Market, by Country

  • 15.1. United States
  • 15.2. Germany
  • 15.3. China
  • 15.4. Japan
  • 15.5. Canada
  • 15.6. France
  • 15.7. India
  • 15.8. United Kingdom
  • 15.9. Mexico
  • 15.10. Italy
  • 15.11. South Korea
  • 15.12. Australia
  • 15.13. Russia
  • 15.14. Brazil
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Becton, Dickinson, and Company
  • 17.2. Hologic, Inc.
  • 17.3. Danaher Corporation
  • 17.4. FUJIFILM Corporation
  • 17.5. GE HealthCare Technologies Inc.
  • 17.6. Siemens Healthineers AG
  • 17.7. CooperSurgical, Inc.
  • 17.8. Medtronic PLC
  • 17.9. Merit Medical Systems, Inc.
  • 17.10. Bio-Rad Laboratories, Inc
  • 17.11. Argon Medical Devices, Inc.
  • 17.12. Sysmex Corporation
  • 17.13. Trivitron Healthcare
  • 17.14. Resitu Medical AB
  • 17.15. A.Menarini Industrie Farmaceutiche Riunite S.r.l.
  • 17.16. Canon Medical Systems Corporation
  • 17.17. Cook Group Incorporated
  • 17.18. Exact Sciences Corporation
  • 17.19. Guardant Health, Inc.
  • 17.20. Halma PLC
  • 17.21. INRAD, Inc.
  • 17.22. Johnson & Johnson Services Inc.
  • 17.23. Koninklijke Philips N.V.
  • 17.24. Medax Srl Unipersonale
  • 17.25. Planmed Oy
  • 17.26. QIAGEN N.V.
  • 17.27. STERYLAB S.r.l.
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. TransMed7, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST BIOPSY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BREAST BIOPSY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BREAST BIOPSY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BREAST BIOPSY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL BREAST BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GUIDANCE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GUIDANCE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GUIDANCE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY GUNS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY GUNS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY GUNS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORE NEEDLE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACUUM-ASSISTED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACUUM-ASSISTED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACUUM-ASSISTED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FINE NEEDLE ASPIRATION BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SURGICAL/OPEN BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SURGICAL/OPEN BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SURGICAL/OPEN BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EXCISIONAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EXCISIONAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EXCISIONAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INCISIONAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INCISIONAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INCISIONAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ULTRASOUND-GUIDED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ULTRASOUND-GUIDED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ULTRASOUND-GUIDED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STEREOTACTIC X-RAY-GUIDED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STEREOTACTIC X-RAY-GUIDED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STEREOTACTIC X-RAY-GUIDED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRI-GUIDED BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI-GUIDED BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRI-GUIDED BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST PARENCHYMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST PARENCHYMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST PARENCHYMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AXILLARY & REGIONAL LYMPH NODES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AXILLARY & REGIONAL LYMPH NODES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AXILLARY & REGIONAL LYMPH NODES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NIPPLE & DUCTAL STRUCTURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NIPPLE & DUCTAL STRUCTURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NIPPLE & DUCTAL STRUCTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMBULATORY SURGERY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EARLY CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RECURRENCE & TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RECURRENCE & TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RECURRENCE & TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. NATO BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. NATO BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 129. NATO BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. G7 BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. G7 BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. G7 BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BREAST BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 250. ITALY BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 251. ITALY BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 252. ITALY BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ITALY BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. AUSTRALIA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 266. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 267. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 268. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN BREAST BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN BREAST BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN BREAST BIOPSY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN BREAST BIOPSY MARKET SIZE, BY SURGICAL/OPEN BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN BREAST BIOPSY MARKET SIZE, BY GUIDANCE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN BREAST BIOPSY MARKET SIZE, BY BIOPSY SITE, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN BREAST BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN BREAST BIOPSY MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 295. GLOBAL BREAST BIOPSY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025